Catalyst Wire Dossier Catalyst Wire Dossier

VVN461 ophthalmic solution

VVN461 · VivaVision Biotech, Inc
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for VVN461 ophthalmic solution, covering 2025-01-27 to 2025-06-10. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery [Phase 2]

See pricing